Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI WW FrankfurtCPhI WW Frankfurt
Not Confirmed
Not Confirmed
28-30 October, 2025
The Battery ShowThe Battery Show
Not Confirmed
Not Confirmed
06-09 October, 2025
Not Confirmed
Not Confirmed
07-09 October, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Not Confirmed
28-30 October, 2025
The Battery ShowThe Battery Show
Industry Trade Show
Not Confirmed
06-09 October, 2025
Industry Trade Show
Not Confirmed
07-09 October, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/we-bridge-the-gap-between-chemistry-and-performance-to-deliver-precise-optimized-micronization-for-complex-apis
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/global-api-micronization-market-set-to-surge-49-by-2030-led-by-specialized-industry-pioneers
12 Aug 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/08/12/3131598/0/en/Mereo-BioPharma-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Corporate-Highlights.html
11 Jul 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/07/09/3112877/20739/en/Ultragenyx-and-Mereo-BioPharma-Announce-UX143-Phase-3-Orbit-Study-for-Osteogenesis-Imperfecta-Progressing-to-Final-Analysis.html
13 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/13/3080008/0/en/Mereo-BioPharma-Reports-First-Quarter-2025-Financial-Results-and-Provides-Corporate-Highlights.html
26 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/26/3049535/0/en/Mereo-BioPharma-Reports-Full-Year-2024-Financial-Results-and-Provides-Corporate-Highlights.html
05 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/05/3037313/0/en/Mereo-BioPharma-to-Participate-in-Fireside-Chat-at-the-Leerink-Partners-Global-Healthcare-Conference.html
12 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/12/3008054/0/en/Mereo-BioPharma-Provides-Update-on-Lead-Clinical-Programs.html
Details:
The net proceeds will be used to fund the clinical advancement of the BPS804 (setrusumab), a monoclonal antibody that is being investigated for the potential treatment of Osteogenesis Imperfecta.
Lead Product(s): Setrusumab,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Jefferies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering June 14, 2024
Lead Product(s) : Setrusumab,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Jefferies
Deal Size : Undisclosed
Deal Type : Public Offering
Mereo BioPharma Prices $50 Million Direct Offering of American Depository Shares
Details : The net proceeds will be used to fund the clinical advancement of the BPS804 (setrusumab), a monoclonal antibody that is being investigated for the potential treatment of Osteogenesis Imperfecta.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
June 14, 2024
Details:
UX143 (setrusumab), is a sclerostin inhibitor antibody drug candidate, which is currently being evaluated for the treatment of osteogenesis imperfecta.
Lead Product(s): Setrusumab,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Antibody, Unconjugated
Recipient: Ultragenyx Pharmaceutical
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 11, 2024
Lead Product(s) : Setrusumab,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Recipient : Ultragenyx Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Ultragenyx & Mereo BioPharma: New Phase 2 Data on Setrusumab in Osteogenesis Imperfecta
Details : UX143 (setrusumab), is a sclerostin inhibitor antibody drug candidate, which is currently being evaluated for the treatment of osteogenesis imperfecta.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 11, 2024
Details:
UX143 (setrusumab) is a fully human monoclonal antibody that inhibits sclerostin, a protein that acts on a key bone-signaling pathway that inhibits the maturation and activity of bone-forming cells in Osteogenesis Imperfecta.
Lead Product(s): Setrusumab,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Antibody, Unconjugated
Recipient: Ultragenyx Pharmaceutical
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 14, 2023
Lead Product(s) : Setrusumab,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Recipient : Ultragenyx Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : UX143 (setrusumab) is a fully human monoclonal antibody that inhibits sclerostin, a protein that acts on a key bone-signaling pathway that inhibits the maturation and activity of bone-forming cells in Osteogenesis Imperfecta.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
October 14, 2023
Details:
UX143 (setrusumab) is a fully human monoclonal antibody that inhibits sclerostin, a protein that acts on a key bone-signaling pathway that inhibits the maturation and activity of bone-forming cells in Osteogenesis Imperfecta.
Lead Product(s): Setrusumab,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Antibody, Unconjugated
Recipient: Ultragenyx Pharmaceutical
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 05, 2023
Lead Product(s) : Setrusumab,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Recipient : Ultragenyx Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : UX143 (setrusumab) is a fully human monoclonal antibody that inhibits sclerostin, a protein that acts on a key bone-signaling pathway that inhibits the maturation and activity of bone-forming cells in Osteogenesis Imperfecta.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 05, 2023
Details:
MPH966 (alvelestat) is an oral drug that is being researched in people with alpha-1 antitrypsin deficiency (AATD) lung disease. It acts to inhibit the neutrophil elastase enzyme and Mereo believes that it has the potential to protect AATD patients from further lung damage.
Lead Product(s): Alvelestat,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 21, 2023
Lead Product(s) : Alvelestat,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MPH966 (alvelestat) is an oral drug that is being researched in people with alpha-1 antitrypsin deficiency (AATD) lung disease. It acts to inhibit the neutrophil elastase enzyme and Mereo believes that it has the potential to protect AATD patients from f...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 21, 2023
Details:
Nivolumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ovarian Neoplasms.
Lead Product(s): Nivolumab,Etigilimab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Recipient: MD Anderson Cancer Center
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 06, 2023
Lead Product(s) : Nivolumab,Etigilimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : MD Anderson Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nivolumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ovarian Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 06, 2023
Details:
Alvelestat (MPH966) is an oral drug that is being researched in people for the treatment of severe Alpha-1 antitrypsin deficiency (AATD) and Bronchiolitis Obliterans Syndrome (BOS).
Lead Product(s): Alvelestat,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 24, 2022
Lead Product(s) : Alvelestat,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022
Details : Alvelestat (MPH966) is an oral drug that is being researched in people for the treatment of severe Alpha-1 antitrypsin deficiency (AATD) and Bronchiolitis Obliterans Syndrome (BOS).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 24, 2022
Details:
Alvelestat (MPH966) is an investigational oral neutrophil elastase inhibitor that is being researched in people with alpha-1 antitrypsin deficiency (AATD) lung disease.
Lead Product(s): Alvelestat,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 17, 2022
Lead Product(s) : Alvelestat,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Alvelestat (MPH966) is an investigational oral neutrophil elastase inhibitor that is being researched in people with alpha-1 antitrypsin deficiency (AATD) lung disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 17, 2022
Details:
The multicenter ACTIVATE study is designed to evaluate the efficacy, safety, tolerability, PK, and pharmacodynamics of MPH-313 (etigilimab), Mereo’s proprietary anti-TIGIT antibody, in combination with a PD-1 inhibitor, nivolumab, with dosing every two weeks.
Lead Product(s): Etigilimab,Nivolumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 12, 2022
Lead Product(s) : Etigilimab,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The multicenter ACTIVATE study is designed to evaluate the efficacy, safety, tolerability, PK, and pharmacodynamics of MPH-313 (etigilimab), Mereo’s proprietary anti-TIGIT antibody, in combination with a PD-1 inhibitor, nivolumab, with dosing every two...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 12, 2022
Details:
Setrusumab (UX143) is a fully human monoclonal antibody that inhibits sclerostin, a protein that acts on a key bone-signaling pathway that inhibits the activity of bone-forming cells.
Lead Product(s): Setrusumab,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Antibody, Unconjugated
Recipient: Ultragenyx Pharmaceutical
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 09, 2022
Lead Product(s) : Setrusumab,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Recipient : Ultragenyx Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
Details : Setrusumab (UX143) is a fully human monoclonal antibody that inhibits sclerostin, a protein that acts on a key bone-signaling pathway that inhibits the activity of bone-forming cells.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 09, 2022
ABOUT THIS PAGE